Research digest / Doses, routes, kinetics
MOTS-c peptide dosage in the research literature
The rodent dose figures (0.5-15 mg/kg/day IP), the routes used, the durations studied, and the honest blank where a validated human dose, frequency, and half-life would go.
Before the details
A direct note on MOTS-c peptide dosage: every dose figure on this page is from animal studies, and none of it is human dosing guidance. "mg/kg" means milligrams of peptide per kilogram of the animal's body weight — a lab measure that does not convert to a human dose. "IP" means intraperitoneal: an injection into the abdominal cavity, a route used in rodents that is not a human administration method. In mice, researchers used roughly 0.5 to 15 mg/kg per day [1][2]. There is no established, validated human dose, frequency, or schedule for MOTS-c.
MOTS-c Dosage in the Research Literature
Published rodent regimens cluster in a wide band. The founding 2015 metabolic study used ~0.5 mg/kg/day IP for chronic dosing (about 8 weeks) and 5 mg/kg/day IP for an acute 7-day protocol in C57BL/6 mice [1]. The 2021 exercise-capacity study used 15 mg/kg/day IP, or 15 mg/kg IP three times weekly, in mice across age groups [2]. Bone studies have used 5 mg/kg/day IP for 12 weeks [1].
So the research dose range is roughly 0.5-15 mg/kg/day IP, depending on the model and endpoint [1][2]. These are doses administered to mice by intraperitoneal injection. They cannot be extrapolated to humans: interspecies dose conversion is not linear, and no human dose-finding work has been done [1][2]. This is the MOTS-c dosage in research, stated as exactly what it is.
How Often Was MOTS-c Dosed in Studies?
Published rodent work used daily or thrice-weekly intraperitoneal injection (for example 15 mg/kg/day or 15 mg/kg 3x/week in aged mice) [2]. There is no validated human dosing frequency.
Daily vs Intermittent Dosing in Studies
Both daily and thrice-weekly intraperitoneal regimens appear in rodent studies; there is no consensus optimal frequency and no validated human schedule [1][2].
Can I Inject MOTS-c Every Day?
This is a research-only question: rodent studies used both daily (15 mg/kg/day) and thrice-weekly regimens, but those are animal protocols [2]. No validated human schedule exists, and MOTS-c is not an approved drug for human use.
MOTS-c Half-Life and Pharmacokinetics
No validated human pharmacokinetic half-life has been published for MOTS-c [1]. As a small unmodified peptide, native MOTS-c is expected to be short-lived in circulation, which is consistent with the fact that published in-vivo work relies on repeated daily or thrice-weekly dosing rather than a single administration [1][2]. Cell-penetrating analogues have been engineered specifically to improve delivery — for example the analogue used in the neuroprotection memory study [5].
Without measured human absorption, distribution, metabolism, and excretion data, statements about how long MOTS-c "lasts" in a person are not supported by the literature [1]. This is the MOTS-c half-life and pharmacokinetics record: an open question, not a published number.
Onset Timeline in Research Studies
Animal studies report metabolic effects over chronic dosing windows of roughly one to eight weeks [1]. No validated human onset timeline has been published.
How Long Did Effects Take in Animal Studies?
In rodent metabolic studies, measurable changes accrued over multi-week dosing (about one to eight weeks) [1]. No validated human time-to-effect exists.
Routes of Administration Studied
The dominant route in rodent MOTS-c research is intraperitoneal (IP) injection — injection into the abdominal cavity [1][2]. Subcutaneous injection appears in some research contexts, and in-vitro work uses cell culture [1]. The neuroprotection study used a cell-penetrating analogue given peripherally to enable brain delivery [5].
MOTS-c is supplied for research as a lyophilized (freeze-dried) powder; reconstitution and storage conditions are vendor- and study-specific, and no standardised human formulation exists [1]. These are laboratory routes documented in published studies, not administration guidance for people.
Treatment Durations Used in Research
Published animal studies ran from about one week (acute) to roughly twelve weeks (chronic, e.g. bone studies) [1]. No human cycle length has been established.
Routes Used in Research
Rodent studies overwhelmingly used intraperitoneal injection, with subcutaneous injection in some research contexts [1][2]. These are laboratory routes, not human administration guidance.
MOTS-c injection: what the studies used
MOTS-c injection in published research means intraperitoneal (and sometimes subcutaneous) injection in rodents [1][2]. There is no human injection protocol, dose, or schedule in the peer-reviewed literature, and MOTS-c is not an FDA-approved injectable drug — see MOTS-c legal status.